AC Immune

Real-time Quotes | Nasdaq Last Sale

Opening 12:49 01/15 EST
Corp Actions
Alzheimer's peers jump after Eli Lilly's donanemab study meets endpoint
Goldman Sachs analyst Terence Flynn said he expected Eli Lilly ([[LLY]] +11.7%) shares to react favorably to positive Phase 2 data of donanemab in Alzheimer's, given that his own expectations
Seekingalpha · 4d ago
AC Immune Reports Competitive Target ALS Foundation Grant To Accelerate Development of Proprietary Phosphorylated TDP-43 Immuno-Assay
AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the receipt of a highly competitive grant awarded by Target
Benzinga · 12/15/2020 13:03
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay
Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital Proprietary SupraAntigenTM platform continues to accelerate development of first- and best-in class antibody therapeutics and...
GlobeNewswire · 12/15/2020 13:00
Is ACIU A Good Stock To Buy Now?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was AC Immune SA (NASDAQ:AC...
Insider Monkey · 12/11/2020 17:54
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immunes Board of Directors
Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune’s scientific leadership in neurodegenerationLAUSANNE, Switzerland, Nov. 20, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Prof. Carl H. June, a world authority on mechanisms related to immune tolerance and adoptive immunotherapy in the fields of chronic inflammation and cancer, was elected to the Company’s Board of Directors, at an extraordinary shareholders’ meeting today.Prof. June is a true pioneer in the field of immunotherapy most well-known for his research into T cell therapies for the treatment of cancer, who, in 2020, was elected to the American Philosophical Society. His expertise can further accelerate AC Immune’s progress in advancing its pipeline of immunotherapies and therapies targeting neuroinflammation.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “We welcome Prof. June’s timely appointment, as neurodegeneration is increasingly linked to inflammatory mechanisms, a key scientific focus for AC Immune’s discovery efforts. His appointment is a further affirmation of our scientific leadership in the neurodegenerative disease field. Prof. June’s significant expertise and standing in the scientific community will be an invaluable asset as we work to develop innovative immunotherapies and target neuroinflammation using our proprietary technology platforms.”Prof. June commented: “I am proud to be invited to join the Board of Directors of AC Immune, an established pioneer at the forefront of discovering and developing treatments for neurodegenerative diseases. It is tremendously exciting to be involved at the cutting edge of research addressing an area with such a high unmet medical need, where immunotherapy and inflammation could play a critically important role. I look forward to working with the outstanding team at AC Immune and hope my own expertise will contribute to their continued success.”Prof. June is Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania. Due to his lifelong work on lymphocyte activation, Prof. June is considered a world authority on mechanisms related to immune tolerance and adoptive immunotherapy in the fields of chronic inflammation and cancer. He and his team pioneered the groundbreaking work in immunotherapy in which patients with refractory and relapsed chronic lymphocytic leukemia are treated with genetically engineered versions of their own T cells. This CAR-T therapy approach, which trains the immune system to attack and destroy cancer cells, has opened a new era of innovative treatments and personalized medicine for cancer patients.Prof. June is a graduate of the Naval Academy in Annapolis, USA, and Baylor College of Medicine in Houston, USA, where he received his medical degree. Prof. June also completed graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle, USA. He has published more than 500 manuscripts and is the recipient of numerous honors and prizes.About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent, and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: US Media Katie Gallagher LaVoie HealthScience Phone: +1 617 792 3937 Email:    Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
GlobeNewswire · 11/20/2020 13:40
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immunes Board of Directors
GlobeNewswire · 11/20/2020 13:40
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
Prof. Streffer is an established authority on neuroscience and biomarker modalities
GlobeNewswire · 11/18/2020 12:02
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
Prof. Streffer is an established authority on neuroscience and biomarker modalities
GlobeNewswire · 11/18/2020 12:02
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACIU. Analyze the recent business situations of AC Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACIU stock price target is 11.15 with a high estimate of 15.84 and a low estimate of 4.993.
Institutional Holdings
Institutions: 77
Institutional Holdings: 21.34M
% Owned: 29.74%
Shares Outstanding: 71.74M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Non-Executive Chairman/Independent Director
Douglas Williams
Chief Executive Officer/Co-Founder/Director/IR Contact Officer
Andrea Pfeifer
Non-Executive Vice Chairman/Independent Director
Martin Velasco
Chief Financial Officer
Joerg Hornstein
Chief Operating Officer/Chief Technology Officer
Piergiorgio Donati
Chief Administrative Officer
Jean-Fabien Monin
Vice President
Julien Rongere
Chief Scientific Officer
Marie Kosco-Vilbois
Non-Executive Independent Director
Peter Bollmann
General Counsel
Alexandre Caratsch
Non-Executive Independent Director
Thomas Graney
Non-Executive Independent Director
Werner Lanthaler
Julian Gray
Non-Executive Independent Director
Roy Twyman
Bojana Portmann
Non-Executive Independent Director
Friedrich von Bohlen und Halbach
Oliver Sol
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Hot Stocks

Webull offers kinds of AC Immune SA stock information, including NASDAQ:ACIU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACIU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACIU stock methods without spending real money on the virtual paper trading platform.